All women will lose bone as a consequence of normal aging and menopause-mediated bone loss due to the estrogen deficiency. However, not all women will develop osteoporosis. The development of osteoporosis can be thought of as an equation [1]: on one side of the equation peak bone mass usually attained by about age 30; on the other side is ongoing bone loss due to normal aging, menopausal-related bone loss, and genetic determinants such as family history, race, and low body mass index, as well as exposures or conditions that are potentially modifiable (i.e., current cigarette smoking, alcohol intake greater than two drinks per day, and chronic glucocorticoid therapy) [2,3]. Taking these factors into account, each woman will have a peak bone mass and a unique set of risk factors for bone loss that determines whether she will experience a non-traumatic fracture or osteoporosis. In postmenopausal women with breast cancer, the relative risks of osteoporotic fractures are higher than women without history of breast cancer [4].Estrogens play a central role in maintaining bone mass [5], and estrogen deficiency whether through natural menopause or as result of treatments for breast cancer such as oophorectomy, gonadotropin-releasing hormone (GnRH) agonist, chemotherapy-induced ovarian failure and aromatase inhibitors, and are associated with bone loss [6][7][8][9]. In order to explore the relationship between estrogens and bone, it useful to review briefly how normal bone maintains its' strength and structural integrity and what happens when estrogen deficiency occurs.Several interrelated factors including geometry, microarchitecture, mineralization of the collagen matrix, and remodeling maintain normal bone [10][11][12]. Remodeling constantly occurs in discreet areas (called remodeling units) and results from a dynamic balance between bone breakdown or resorption, mediated by osteoclasts, and new bone formation, mediated by osteoblasts. The regulation of remodeling is complex involving systemic hormones such estrogens, androgens and parathyroid hormone as well as locally produced autocrine and paracrine factors within the microenvironment of bone [13]. A prime example of these local factors within the remodeling unit is receptor activator for nuclear factor-jB (RANKL) ligand, the RANK receptor, and osteoprotegerin (OPG) [14,15].RANKL, a member of the tumor necrosis factor (TNF) family, is produced by osteoblasts and binds to the RANK receptor on osteoclasts. Ligand binding stimulates hematopoietic precursors to differentiate into multinucleated osteoclasts and activates osteoclasts to increase bone resorption [15]. Likewise, OPG is secreted from osteoblasts and binds RANKL and decreases osteoclast-mediated bone resorption. Simply stated RANKL drives resorption, OPG puts the brakes on, and the ratio between them governs normal remodeling, osteoporosis, other metabolic bone diseases, and tumor-related osteoclast activation [1,16].The ratio of RANKL to OPG is influenced by estrogens as well other hormones, cytokines, and gr...